Silexion Therapeutics Corp (SLXNW) Aandelenanalyse

Bedrijfsoverzicht

Silexion Therapeutics Corp is a biopharmaceutical entity dedicated to the discovery and development of RNA interference (RNAi)-based therapeutics and delivery systems specifically designed to target malignant solid tumors. The company operates within the biotechnology and pharmaceutical sectors, focusing on the utilization of its proprietary LODER delivery platform to address challenges associated with treating solid tumor malignancies. As of the latest available data, the company employs 13 individuals and maintains a market capitalization and annual revenue that are currently not disclosed in public financial records. The absence of disclosed market cap and revenue figures indicates that Silexion operates as a pre-revenue or early-stage development entity, a common characteristic for biopharmaceutical firms that prioritize research and development expenditures over immediate commercial sales. This structural position suggests that the company's primary value proposition currently resides in its intellectual property portfolio and the potential future commercialization of its RNAi assets rather than established cash-generating operations.

Financiële gezondheid

The company reported a net income loss of $-11,912,000 over the trailing twelve months, while its EBITDA stood at $-11,618,000, reflecting significant operational expenditures typical of the clinical development phase. The gap between the reported revenue, which is not disclosed, and the substantial net loss reveals a cost structure heavily weighted toward research, development, and potentially administrative overheads rather than cost of goods sold. Free cash flow for the period was $-6,507,125, indicating that the company is consuming cash to fund its operations and development pipeline rather than generating liquidity from current business activities. All three margin metrics—gross margin, operating margin, and profit margin—are recorded at 0.0%, which is indicative of a company that has not yet achieved commercial profitability or has not recognized significant revenue against its substantial operating costs. The balance sheet shows a cash position of $5.99M against total debt of $2.04M, resulting in a debt-to-equity ratio of 78.22, which suggests a leveraged capital structure relative to its equity base. Despite the debt presence, the current ratio of 2.41 indicates a strong short-term liquidity position, as the company holds significantly more current assets than current liabilities, providing a buffer for near-term obligations. Return on equity is not available due to the lack of profitability, while return on assets is reported at -144.3%, highlighting the heavy asset utilization costs relative to the negative asset base generated by the company's operations.

Waarderingsbeoordeling

Trailing and forward P/E ratios are not available (N/A) because the company is currently unprofitable, meaning these traditional valuation metrics cannot be calculated and imply an expected earnings trajectory that has not yet materialized into positive net income. The price-to-book ratio is 0.03, which indicates that the market values the company at a fraction of its net asset value, suggesting a significant discount or a market skepticism regarding the recoverability of its book assets given its development stage. Price-to-sales and EV/EBITDA ratios are not available (N/A), reflecting the absence of sales data and positive earnings necessary to compute these alternative valuation metrics, which often leaves biotech stocks reliant on other forms of assessment. The 52-week price range spans from a low of $0.01 to a high of $0.03, meaning the stock is currently trading at or near the upper bound of its annual volatility range, specifically at 100% of the 52-week low or 0% below the 52-week high depending on the precise current pricing moment, but strictly bounded by these historical extremes. The beta value is 0.06, which signifies that the stock's price volatility is extremely low relative to the broader market, likely due to its small market capitalization and lack of correlation with general market movements.

Growth & Income

Revenue growth year-over-year and earnings growth year-over-year are not available (N/A), as the company has not yet generated consistent positive revenue streams to calculate growth rates against prior periods. Since the company is not a dividend payer, there is no dividend yield or payout ratio to evaluate, which implies that the firm reinvests all available cash flow, including its cash reserves, back into its research and development efforts rather than distributing returns to shareholders. The overall growth and income profile is characterized by a complete absence of current financial returns, with all financial resources directed toward the long-term goal of bringing RNAi-based cancer drugs to market. This profile is typical for early-stage biopharmaceutical companies that forgo immediate income generation to accelerate the clinical progression of their proprietary solid tumor treatment platforms.